The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Seed VC | Alive

Total Raised


Last Raised

$3.25M | 2 yrs ago

About Ikarovec

Ikarovec develops gene therapies to treat major ophthalmic indications. Its lead program is a multicistronic gene therapy for diabetic macular edema, to IND-enabling studies.

Ikarovec Headquarter Location

Cambridge, England,

United Kingdom

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Ikarovec

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Ikarovec is included in 3 Expert Collections, including Regenerative Medicine.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.



1,750 items

Latest Ikarovec News

Ikarovec one of Scrip’s ‘10 To Watch’ at BIO-Europe Digital,...

Oct 5, 2020

Ikarovec one of Scrip’s ‘10 To Watch’ at BIO-Europe Digital, October 26-29 Company presentation & partnering opportunities now available online Ikarovec , which is developing novel gene therapies to treat major ophthalmic indications, is pleased to announce that it has been named one of Scrip’s ’10 To Watch’ companies at Bio-Europe Digital. This is a nomination for emerging companies displaying promise in drug discovery and development. BIO-Europe 2020 is being delivered digitally. The opportunity to view Ikarovec’s presentation and book a partnering meeting with the Executive Chairman, Dr Robert Haigh, is available here . Dr Haigh’s presentation discusses the potential of the company’s approach in devastating eye diseases, and its progress since inception. Ikarovec launched earlier this year with £2.5m of seed funding from UKI2S with co-investment from LifeArc and Parkwalk. Primary use of funds is to take the company’s lead programme, a multicistronic gene therapy for diabetic macular edema, to IND-enabling studies. It was recently awarded a £458,740 Innovate UK grant for one of its earlier stage programmes in wet age-related macular degeneration. Ikarovec has recently taken laboratory and office space in the Innovation Centre at Norwich Research Park, with access to shared scientific facilities. The location also brings proximity to Norwich Medical School and a clinical trials unit which will be valuable as the company develops. –ENDS— Robert Haigh, Executive Chairman

  • When was Ikarovec founded?

    Ikarovec was founded in 2019.

  • Where is Ikarovec's headquarters?

    Ikarovec's headquarters is located at Cambridge.

  • What is Ikarovec's latest funding round?

    Ikarovec's latest funding round is Seed VC.

  • How much did Ikarovec raise?

    Ikarovec raised a total of $3.25M.

  • Who are the investors of Ikarovec?

    Investors of Ikarovec include UK Innovation & Science Seed Fund, Parkwalk Advisors and LifeArc.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.